218 related articles for article (PubMed ID: 15855007)
1. Enhancement of CD4 and CD8 immunity by anti-CD137 (4-1BB) monoclonal antibodies during hepatitis C vaccination with recombinant adenovirus.
Arribillaga L; Sarobe P; Arina A; Gorraiz M; Borrás-Cuesta F; Ruiz J; Prieto J; Chen L; Melero I; Lasarte JJ
Vaccine; 2005 May; 23(27):3493-9. PubMed ID: 15855007
[TBL] [Abstract][Full Text] [Related]
2. Induction of potent and long-lasting CD4 and CD8 T-cell responses against hepatitis C virus by immunization with viral antigens plus poly(I:C) and anti-CD40.
Zabaleta A; Arribillaga L; Llopiz D; Dotor J; Lasarte JJ; Prieto J; Borrás-Cuesta F; Esteban JI; Quer J; Vayreda F; Sarobe P
Antiviral Res; 2007 Apr; 74(1):25-35. PubMed ID: 17275104
[TBL] [Abstract][Full Text] [Related]
3. Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells.
May KF; Chen L; Zheng P; Liu Y
Cancer Res; 2002 Jun; 62(12):3459-65. PubMed ID: 12067989
[TBL] [Abstract][Full Text] [Related]
4. Enhanced and sustained CD8+ T cell responses with an adenoviral vector-based hepatitis C virus vaccine encoding NS3 linked to the MHC class II chaperone protein invariant chain.
Mikkelsen M; Holst PJ; Bukh J; Thomsen AR; Christensen JP
J Immunol; 2011 Feb; 186(4):2355-64. PubMed ID: 21257961
[TBL] [Abstract][Full Text] [Related]
5. 4-1BB and OX40 stimulation enhance CD8 and CD4 T-cell responses to a DNA prime, poxvirus boost vaccine.
Munks MW; Mourich DV; Mittler RS; Weinberg AD; Hill AB
Immunology; 2004 Aug; 112(4):559-66. PubMed ID: 15270726
[TBL] [Abstract][Full Text] [Related]
6. Vigorous hepatitis C virus-specific CD4+ and CD8+ T cell responses induced by protein immunization in the presence of Montanide ISA720 plus synthetic oligodeoxynucleotides containing immunostimulatory cytosine-guanine dinucleotide motifs.
Sugauchi F; Wang RY; Qiu Q; Jin B; Alter HJ; Shih JW
J Infect Dis; 2006 Feb; 193(4):563-72. PubMed ID: 16425136
[TBL] [Abstract][Full Text] [Related]
7. Protective vaccination with hepatitis C virus NS3 but not core antigen in a novel mouse challenge model.
El-Gogo S; Staib C; Lasarte JJ; Sutter G; Adler H
J Gene Med; 2008 Feb; 10(2):177-86. PubMed ID: 18076128
[TBL] [Abstract][Full Text] [Related]
8. Modulation of vaccine-induced immune responses to hepatitis C virus in rhesus macaques by altering priming before adenovirus boosting.
Rollier C; Verschoor EJ; Paranhos-Baccala G; Drexhage JA; Verstrepen BE; Berland JL; Himoudi N; Barnfield C; Liljestrom P; Lasarte JJ; Ruiz J; Inchauspe G; Heeney JL
J Infect Dis; 2005 Sep; 192(5):920-9. PubMed ID: 16088843
[TBL] [Abstract][Full Text] [Related]
9. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation.
Kim JA; Averbook BJ; Chambers K; Rothchild K; Kjaergaard J; Papay R; Shu S
Cancer Res; 2001 Mar; 61(5):2031-7. PubMed ID: 11280763
[TBL] [Abstract][Full Text] [Related]
10. Vaccination with an adenoviral vector encoding hepatitis C virus (HCV) NS3 protein protects against infection with HCV-recombinant vaccinia virus.
Arribillaga L; de Cerio AL; Sarobe P; Casares N; Gorraiz M; Vales A; Bruna-Romero O; Borrás-Cuesta F; Paranhos-Baccala G; Prieto J; Ruiz J; Lasarte JJ
Vaccine; 2002 Dec; 21(3-4):202-10. PubMed ID: 12450695
[TBL] [Abstract][Full Text] [Related]
11. Enhanced T cell responses against hepatitis C virus by ex vivo targeting of adenoviral particles to dendritic cells.
Echeverria I; Pereboev A; Silva L; Zabaleta A; Riezu-Boj JI; Bes M; Cubero M; Borras-Cuesta F; Lasarte JJ; Esteban JI; Prieto J; Sarobe P
Hepatology; 2011 Jul; 54(1):28-37. PubMed ID: 21452282
[TBL] [Abstract][Full Text] [Related]
12. A novel combined vaccine candidate containing epitopes of HCV NS3, core and E1 proteins induces multi-specific immune responses in BALB/c mice.
Zeng R; Li G; Ling S; Zhang H; Yao Z; Xiu B; He F; Huang R; Wei L
Antiviral Res; 2009 Oct; 84(1):23-30. PubMed ID: 19646486
[TBL] [Abstract][Full Text] [Related]
13. Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV.
Forns X; Payette PJ; Ma X; Satterfield W; Eder G; Mushahwar IK; Govindarajan S; Davis HL; Emerson SU; Purcell RH; Bukh J
Hepatology; 2000 Sep; 32(3):618-25. PubMed ID: 10960458
[TBL] [Abstract][Full Text] [Related]
14. Recombinant adenoviral vector expressing HCV NS4 induces protective immune responses in a mouse model of Vaccinia-HCV virus infection: a dose and route conundrum.
Singh S; Vedi S; Li W; Samrat SK; Kumar R; Agrawal B
Vaccine; 2014 May; 32(23):2712-21. PubMed ID: 24631092
[TBL] [Abstract][Full Text] [Related]
15. 4-1BB promotes long-term survival in skin allografts treated with anti-CD45RB and anti-CD40L monoclonal antibodies.
Lee J; Lee EN; Kim EY; Lee HJ; Park HJ; Sun CL; Lee SK; Joh JW; Lee KW; Kwon GY; Kim SJ
Transplant Proc; 2005; 37(1):123-5. PubMed ID: 15808569
[TBL] [Abstract][Full Text] [Related]
16. Induction of potent cellular immune response in mice by hepatitis C virus NS3 protein with double-stranded RNA.
Jin B; Wang RY; Qiu Q; Sugauchi F; Grandinetti T; Alter HJ; Shih JW
Immunology; 2007 Sep; 122(1):15-27. PubMed ID: 17451465
[TBL] [Abstract][Full Text] [Related]
17. Engagement of the CD137 (4-1BB) costimulatory molecule inhibits and reverses the autoimmune process in collagen-induced arthritis and establishes lasting disease resistance.
Foell JL; Diez-Mendiondo BI; Diez OH; Holzer U; Ruck P; Bapat AS; Hoffmann MK; Mittler RS; Dannecker GE
Immunology; 2004 Sep; 113(1):89-98. PubMed ID: 15312139
[TBL] [Abstract][Full Text] [Related]
18. Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines.
Ito F; Li Q; Shreiner AB; Okuyama R; Jure-Kunkel MN; Teitz-Tennenbaum S; Chang AE
Cancer Res; 2004 Nov; 64(22):8411-9. PubMed ID: 15548712
[TBL] [Abstract][Full Text] [Related]
19. Priming with two DNA vaccines expressing hepatitis C virus NS3 protein targeting dendritic cells elicits superior heterologous protective potential in mice.
Guan J; Deng Y; Chen H; Yin X; Yang Y; Tan W
Arch Virol; 2015 Oct; 160(10):2517-24. PubMed ID: 26215441
[TBL] [Abstract][Full Text] [Related]
20. Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4-1BB), and their role in the generation of anti-tumor immune responses.
Taraban VY; Rowley TF; O'Brien L; Chan HT; Haswell LE; Green MH; Tutt AL; Glennie MJ; Al-Shamkhani A
Eur J Immunol; 2002 Dec; 32(12):3617-27. PubMed ID: 12516549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]